Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Metastasiertes kastrationsresistentes Prostatakarzinom

Phase-III-Studie zu Olaparib plus Abirateron als Erstlinientherapie

This is a preview of subscription content, log in to check access.

Abb. 1

Author information

Correspondence to Heidrun Rexer.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Rexer, H. Phase-III-Studie zu Olaparib plus Abirateron als Erstlinientherapie. Uro-News 24, 16–17 (2020). https://doi.org/10.1007/s00092-020-4049-1

Download citation